Navigare Ventures
Navigare Ventures is an early-stage investment firm based in Stockholm, Sweden, established in 2021 as the venture arm of Wallenberg Investments. The firm specializes in investing in science-driven companies that are focused on advanced computing, quantum technologies, synthetic biology, bio-innovation, advanced materials, nanotechnology, and data-driven life sciences. By targeting these sectors, Navigare Ventures aims to support innovative enterprises at the forefront of scientific advancement.
Elypta AB is a molecular diagnostic company based in Stockholm, Sweden, focused on developing a metabolism-based liquid biopsy platform for the early detection and monitoring of cancer. Founded in 2017, Elypta's platform utilizes a new in vitro diagnostic laboratory assay kit to measure biomarkers in blood and urine, employing artificial intelligence algorithms to analyze data for cancer signatures. The company is actively involved in the clinical trial series AURORAX, which investigates the application of its technology in renal cell carcinoma, addressing aspects such as recurrence surveillance and treatment response monitoring. Elypta is exploring its platform's potential across various cancer indications, aiming to enhance early-stage cancer detection and improve patient outcomes.
Peafowl Solar Power AB, founded in 2018 and based in Uppsala, Sweden, specializes in the manufacturing of innovative solar and photovoltaic cells. The company focuses on producing highly transparent, affordable, efficient, and stable solar cells designed to power a variety of devices, including Internet of Things (IoT) applications, sensors, wearables, and smart glasses. Through its advanced technology, Peafowl aims to enhance the energy efficiency and functionality of modern electronic devices.
Elypta AB is a molecular diagnostic company based in Stockholm, Sweden, focused on developing a metabolism-based liquid biopsy platform for the early detection and monitoring of cancer. Founded in 2017, Elypta's platform utilizes a new in vitro diagnostic laboratory assay kit to measure biomarkers in blood and urine, employing artificial intelligence algorithms to analyze data for cancer signatures. The company is actively involved in the clinical trial series AURORAX, which investigates the application of its technology in renal cell carcinoma, addressing aspects such as recurrence surveillance and treatment response monitoring. Elypta is exploring its platform's potential across various cancer indications, aiming to enhance early-stage cancer detection and improve patient outcomes.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.